Hejian Zou

Deep Immunophenotyping Unravels the Double Negative T cells and PD-1-Mediated Inflammatory Exhaustion in Ankylosing Spondylitis

Lu Bai, Jian Gao, Yunyun Xu, Yuexin Yu et autres

Abstract Ankylosing spondylitis (AS) is a chronic, immune-mediated inflammatory disorder primarily affecting the axial skeleton. It is characterized by bony fusion and syndesmophyte formation of the spine, leading to compromised mobility, reduced quality of life and increased mortality. However, the underlying immune …

cn (code pays fourni par la source)

Corrigendum to “Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway” [J. Dermatol. Sci. 87 (2017) 149–158]

Xiaoxia Zhu, Haiyan Chu, Shuai Jiang, Qingmei Liu et autres

cn, us (code pays fourni par la source)

SSGJ ‐613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double‐Blind, Phase II Study

Yu Xue, Xiaoxia Zhu, Baoyu Zhang, Yanlin Li et autres

OBJECTIVES: This phase II trial aimed to evaluate the efficacy and safety of SSGJ-613, a fully human anti-interleukin 1β monoclonal antibody, compared with compound betamethasone (CB) in Chinese patients with acute gouty arthritis. METHODS: In this multicenter, double-blind, double-dummy, active-controlled study, 90 …

cn (code pays fourni par la source)

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/ II Clinical Trial

Yu Xue, Ning Zhang, Jiankang Hu, Wei Gou et autres

ABSTRACT Aim This Phase Ib/II study aimed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Firsekibart in the treatment of gout flares. Methods Phase Ib part utilized an open‐label, single‐dose, dose‐escalation design. Patients were enrolled and received a single subcutaneous injection …

cn (code pays fourni par la source)

Expert consensus on urate‑lowering therapy for high‑risk hyperuricemia (2026 edition)

Xi Zhu, Yingqian MO, Lihua Duan, 青玉凤 et autres

Hyperuricemia (HUA) is a common chronic condition diagnosed when serum uric acid (SUA) exceeds 420 μmol/L (7.0 mg/dL) on two separate occasions. The prevalence of HUA in China has shown a marked upward trend, increasing from 11.1% in 2015–2016 to 14.0% in …

cn (code pays fourni par la source)

Fibroblast Mitochondrial Ca 2+ Overload Drives Skin Fibrosis via Mitochondrial DNA Leakage and Cyclic GMP ‐ AMP Synthase–Stimulator of Interferon Genes Activation in Systemic Sclerosis

Xiaoyun Zhang, Yingyu Wang, Hai Huang, Xinyi Guo et autres

Objective To explore the clinical relevance of mitochondrial DNA (mtDNA) in systemic sclerosis (SSc) and elucidate the mechanism by which mtDNA leakage drives fibroblast activation. Methods Plasma mtDNA was quantified by quantitative polymerase chain reaction in 50 patients with SSc and 20 …

cn (code pays fourni par la source)

Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial

Zaihua Zhu, Yu Xue, Tianshu Chu, Jiankang Hu et autres

INTRODUCTION: Patients with recurrent acute gout flares who are unable to use nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine have limited alternatives and remain at high risk of flare recurrence. Firsekibart is a fully human monoclonal antibody targeting interleukin-1βeta (IL-1β) The objective of …

cn (code pays fourni par la source)

Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate‐Lowering Therapy: A Phase 2, Randomized, Open‐Label, Multicenter, Active‐Controlled Trial

Yiyun Yu, Yu Xue, Jiankang Hu, Ning Zhang et autres

OBJECTIVE: To evaluate the efficacy and safety of firsekibart versus colchicine for prophylaxis against acute gout flares in participants initiating urate-lowering therapy (ULT). METHODS: In this randomized, multicenter, open-label, active-controlled, phase 2 trial, participants were randomized (1:1:1) to receive a single subcutaneous …

cn (code pays fourni par la source)

Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial

Ning Kong, Yu Xue, Li Mao, Long Qian et autres

INTRODUCTION: Firsekibart, an anti-interleukin (IL)-1β monoclonal antibody, has demonstrated more sustained control of gout flares compared with compound betamethasone in previous clinical studies. This study evaluated the efficacy and safety of firsekibart versus etoricoxib for the treatment of frequent gout flares. METHODS: …

cn (code pays fourni par la source)

Mitochondrial dysfunction in fibrotic diseases: Research progress and MSC-exos therapy

Xiaoyun Zhang, Yingyu Wang, Xinyi Guo, Weiguo Wan et autres

Fibrosis is a common pathological feature of most chronic diseases progressing to the end stage, with its specific pathogenesis still unclear and lacking effective therapeutic approaches. Mitochondria are essential organelles responsible for energy production and the maintenance of cellular homeostasis. Increasing evidence …

cn (code pays fourni par la source)

Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial

Xue Fei Yu, Tianshu Chu, Jiankang Hu, Wei Gou et autres

< 0.0001). Efficacy was consistent across subgroups. Treatment-emergent adverse events occurred in 71.2% of Firsekibart-treated patients and 69.9% of those receiving CB. In conclusion, Firsekibart is effective and well tolerated for acute gout flares in patients unsuitable for standard therapy, demonstrating non-inferiority …

cn (code pays fourni par la source)

Desiccation-induced DNA damage facilitates drug resistance in Mycobacterium tuberculosis

Collette D. Brown, Brenda Lee, Han Liu, Airong Wu et autres

ABSTRACT Mycobacterium tuberculosis (Mtb) is an obligate human pathogen that depends on its ability to spread from host-to-host to survive as a species. Yet, knowledge of transmission-specific traits remains lacking. Here, we report the discovery of a specific adaptive response to desiccation, …

us, qa (code pays fourni par la source)